Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Surgery Partners Earnings Perspective: Return On Invested Capital

Pulled from Benzinga Pro data, Surgery Partners (NASDAQ:SGRY) posted Q1 earnings of $42.80 million, an increase from Q4 of 0.23%. Sales dropped to $596.20 million, a 2.29% decrease between quarters.

Benzinga

Daseke Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, Daseke (NASDAQ:DSKE) earned $13.00 million, a 83.1% increase from the preceding quarter. Daseke also posted a total of $421.00 million in sales, a 6.77% increase since Q4.

Benzinga

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Harmony Biosciences Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Harmony Biosciences (NASDAQ:HRMY) posted Q1 earnings of $21.48 million, an increase from Q4 of 5.41%. Sales dropped to $85.31 million, a 6.47% decrease between quarters.

Benzinga

Esperion Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but Esperion Therapeutics still reported an overall loss of $56.73 million.

Benzinga

Kymera Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter.

Benzinga

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

LGI Homes's Return On Capital Employed Overview

Pulled from Benzinga Pro data, LGI Homes (NASDAQ:LGIH) posted Q1 earnings of $78.69 million, an increase from Q4 of 29.3%. Sales dropped to $546.05 million, a 31.84% decrease between quarters.

Benzinga

If Steve Jobs Had His Way, iPhone Won't Have A SIM Card Slot

If it was up to Apple Inc (NASDAQ: AAPL) co-founder Steve Jobs, the iPhone of today would look very different and for one it wouldn’t have a SIM card tray, revealed the “father of the iPod” Tony Fadell in a recent interview.

Benzinga

Why Mullen Automotive Shares Are Surging Today

Mullen Automotive Inc (NASDAQ:MULN) reported preliminary cash and equivalents of $65.2 million as of Q2-end, primarily due to $43.9 million from the issuance of Series C Preferred Stock and associated warrants. Additionally, the company received $29.6 million in net proceeds under the $30 million Esousa Equity Line, dated September 1, 2021. Total assets…

Benzinga

Where Palo Alto Networks Stands With Analysts

Palo Alto Networks (NASDAQ:PANW) has observed the following analyst ratings within the last quarter:

Benzinga

Expert Ratings for Royalty Pharma

Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:

Benzinga

What 4 Analyst Ratings Have To Say About James River Gr Hldgs

Over the past 3 months, 4 analysts have published their opinion on James River Gr Hldgs (NASDAQ:JRVR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Peering Into SoFi Technologies's Recent Short Interest

SoFi Technologies's (NASDAQ:SOFI) short percent of float has risen 4.9% since its last report. The company recently reported that it has 141.71 million shares sold short, which is 22.48% of all regular shares that are available for trading.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Peering Into Rivian Automotive's Recent Short Interest

Rivian Automotive's (NASDAQ:RIVN) short percent of float has risen 3.89% since its last report. The company recently reported that it has 51.71 million shares sold short, which is 10.95% of all regular shares that are available for trading.

Benzinga

Where Arhaus Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Arhaus (NASDAQ:ARHS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Why Embecta Shares Are Falling Today

Becton Dickinson and Co's (NYSE:BDX) pure-play diabetes spin-off Embecta Corp (NASDAQ:EMBC) has reported Q2 sales of $274.5 million, down 3.4% on a reported basis, down 1.3% on a constant currency basis. Of the decrease, $6.0 million was attributable to unfavorable effects from foreign currency translation. Volume unfavorably impacted revenues by approximately $3.7 million, primarily…

Benzinga

Sol-Gel Technologies: Q1 Earnings Insights

Sol-Gel Technologies (NASDAQ:SLGL) reported its Q1 earnings results on Friday, May 13, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: ProPhase Labs Q1 Earnings

ProPhase Labs (NASDAQ:PRPH) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

10 Biggest Price Target Changes For Friday

Barclays cut the price target on Avis Budget Group, Inc. (NASDAQ: CAR) from $245 to $223. Avis Budget shares rose 2.3% to $224.98 in pre-market trading.

Benzinga

My Size Shares Soar Following Q1 Results

My Size, Inc (NASDAQ:MYSZ) reported first-quarter FY22 revenue growth of 1400% year-on-year to $0.4 million, primarily attributable to closing the acquisition of Orgad on February 7. MySizeID revenue increased 63% Y/Y to $0.04 million. Gross profit rose 467% Y/Y to $0.15 million. The gross margin deteriorated from 100% to 37.9% due to the…

Benzinga

Morning Brief: Top Financial Stories Dominating on Friday, May 13

CNBC

Benzinga

3 Implications From Elon Musk Putting Twitter Deal On Hold

Elon Musk spooked the market with his early Friday tweet that the Twitter, Inc. (NASDAQ: TWTR) deal is on hold.

Benzinga

Organigram Q2 Fiscal 2022 Revenue Grows 117% YoY Primaraly Because Of This

Organigram Holdings Inc. (NASDAQ: OGI) (TSX:OGI), the parent company of Organigram Inc., released its results for the second quarter ended February 28, 2022.

Benzinga

Recap: Longeveron Q1 Earnings

Longeveron (NASDAQ:LGVN) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1 … 497 498 499 500

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.